Skip to content
Search

Latest Stories

Submit Guest Post

Indian court declines interim relief to Vedanta owned Sterlite

AN INDIAN court yesterday (1) declined to provide any interim comfort to Vedanta owned Sterlite to conduct maintenance work at its closed copper smelter unit in Tuticorin of the southern Indian state, Tamil Nadu.

The Madras high court posted the matter to March 27 for further hearing. The bench has also asked the Tamil Nadu Pollution Control Board (TNPCB) to file its reply by then inconnection with the case.


Sterlite in its plea filed according to the recent suggestion of the country’s top court, has questioned the May 23, 2018 orders of TNPCB refusing the renewal consent to the plant as well as permanent closure, terming them as wholly illegal, unconstitutional and ultra vires.

Earlier,Tamil Nadu state government ordered the permanent shutdown of the plant in the wake of violent protests against Sterlite that led to death of 13 people in police firing last year.

The local residents were protesting against environment pollution being allegedly caused by the copper smelter.

India’s apex court on February 18 had set aside the order of the country’s environment court permitting the opening of the plant but gave a choice to the firm to approach the high court against the closure order.

Add EasternEye As Your Trusted Source
preferred source on google news

More For You

AstraZeneca

AstraZeneca chief executive Pascal Soriot says the company has the science, pipeline and team to deliver its long-term growth ambitions

Getty Images

AstraZeneca targets $80bn revenue by 2030 with $1.5bn savings and pipeline investment

  • AstraZeneca expects its restructuring programme to generate $1.5bn in annualised savings by 2029, with most of the money reinvested in research and development.
  • The plan could incur up to $2bn in one-off restructuring costs, although the company expects its overall workforce to continue growing.
  • Third-quarter revenue rose 7 per cent to $16.21bn, while oncology sales increased 17 per cent to $7.77bn.

AstraZeneca has unveiled plans to generate around $1.5bn in annual savings through a three-year restructuring programme, as chief executive Pascal Soriot shifts the focus back to growth and investment in its drug pipeline.

The British-based pharmaceutical group said its Reshaping for Sustainable Growth programme would redirect resources towards research and development, particularly its pipeline of more than 180 projects and emerging technologies.

Keep ReadingShow less